Sabby Management, Llc Buys Sorrento Therapeutics Inc, AstraZeneca PLC, Immunomedics Inc, Sells Biogen Inc, SELECT SECTOR SPDR, Xeris Pharmaceuticals Inc

• New Purchases: SRNE, IMMU, ACAD, RMTI, SPI, ITCI, CIDM, VXX, CKPT, COCP, SHIP, V9G, N18A, NVCN, BLU, DXR, EYEN, CNTG, AFIB, SPCB, PDSB, TTNP, E8L, AKER, BBI, CYCC, USEG, MKGI, ALT, HEPA, CLBS, NBRV, EVOK, CTXR, BIOL, ZOM, BKYI,
• Added Positions: AZN, MRNA, PULM, INO, LPCN, RKDA, ODT, GNCA, PSTI, IBB, CVM, SNCA, LMFA, NSPR, PHAS,
• Reduced Positions: BIIB, XLV, CRIS, SCPH, NRBO, AVEO, AUPH, FGEN,
• Sold Out: XERS, PLL, ALNA, GLBS, CLDX, SOLY, G5Z3, MBIO, AVGR, IMUX, YTRA, GNPX, POAI, ATNM, AIKI, XBI, BPTH, HOTH, MARK, ENLV, RWLK,

For the details of SABBY MANAGEMENT, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/sabby+management%2C+llc/current-portfolio/portfolio

1. Biogen Inc (BIIB) - 44,536 shares, 11.96% of the total portfolio. Shares reduced by 57.14%
2. Moderna Inc (MRNA) - 121,975 shares, 8.17% of the total portfolio. Shares added by 69.66%
3. AstraZeneca PLC (AZN) - 147,945 shares, 7.67% of the total portfolio. Shares added by 372.37%
4. Sorrento Therapeutics Inc (SRNE) - 606,298 shares, 6.40% of the total portfolio. New Position
5. Immunomedics Inc (IMMU) - 50,000 shares, 4.02% of the total portfolio. New Position

Sabby Management, Llc initiated holding in Sorrento Therapeutics Inc. The purchase prices were between $6.17 and $18.82, with an estimated average price of $9.08. The stock is now traded at around $6.67. The impact to a portfolio due to this purchase was 6.4%. The holding were 606,298 shares as of .

Sabby Management, Llc initiated holding in Immunomedics Inc. The purchase prices were between $36.91 and $85.53, with an estimated average price of $50.24. The stock is now traded at around $87.86. The impact to a portfolio due to this purchase was 4.02%. The holding were 50,000 shares as of .

Sabby Management, Llc initiated holding in ACADIA Pharmaceuticals Inc. The purchase prices were between $36.42 and $57, with an estimated average price of $43.24. The stock is now traded at around $54.80. The impact to a portfolio due to this purchase was 3.9%. The holding were 99,921 shares as of .

Sabby Management, Llc initiated holding in Rockwell Medical Inc. The purchase prices were between $1.04 and $2.08, with an estimated average price of $1.57. The stock is now traded at around $0.98. The impact to a portfolio due to this purchase was 3.64%. The holding were 3,595,415 shares as of .

Sabby Management, Llc initiated holding in SPI Energy Co Ltd. The purchase prices were between $1.01 and $14, with an estimated average price of $2.11. The stock is now traded at around $8.28. The impact to a portfolio due to this purchase was 2.9%. The holding were 425,762 shares as of .

Sabby Management, Llc initiated holding in Intra-Cellular Therapies Inc. The purchase prices were between $17.61 and $31.86, with an estimated average price of $22.76. The stock is now traded at around $27.75. The impact to a portfolio due to this purchase was 2.79%. The holding were 115,000 shares as of .

Sabby Management, Llc added to a holding in AstraZeneca PLC by 372.37%. The purchase prices were between $53.07 and $61.1, with an estimated average price of $55.53. The stock is now traded at around $55.18. The impact to a portfolio due to this purchase was 6.05%. The holding were 147,945 shares as of .

Sabby Management, Llc added to a holding in Moderna Inc by 69.66%. The purchase prices were between $54.34 and $94.85, with an estimated average price of $69.45. The stock is now traded at around $92.59. The impact to a portfolio due to this purchase was 3.35%. The holding were 121,975 shares as of .

Sabby Management, Llc added to a holding in Pulmatrix Inc by 14473.53%. The purchase prices were between $0.98 and $1.93, with an estimated average price of $1.28. The stock is now traded at around $1.09. The impact to a portfolio due to this purchase was 1.95%. The holding were 1,740,663 shares as of .

Sabby Management, Llc added to a holding in Inovio Pharmaceuticals Inc by 6144.20%. The purchase prices were between $9.57 and $27.05, with an estimated average price of $17.32. The stock is now traded at around $11.84. The impact to a portfolio due to this purchase was 1.35%. The holding were 124,884 shares as of .

Sabby Management, Llc added to a holding in Lipocine Inc by 2968.56%. The purchase prices were between $1.21 and $2.23, with an estimated average price of $1.55. The stock is now traded at around $1.44. The impact to a portfolio due to this purchase was 0.57%. The holding were 443,469 shares as of .

Sabby Management, Llc added to a holding in Arcadia Biosciences Inc by 362.06%. The purchase prices were between $2.54 and $3.94, with an estimated average price of $3.38. The stock is now traded at around $3.10. The impact to a portfolio due to this purchase was 0.57%. The holding were 275,123 shares as of .

Sabby Management, Llc sold out a holding in Xeris Pharmaceuticals Inc. The sale prices were between $2.58 and $6.59, with an estimated average price of $3.99.

Sabby Management, Llc sold out a holding in Piedmont Lithium Ltd. The sale prices were between $5.52 and $37, with an estimated average price of $8.02.

Sabby Management, Llc sold out a holding in Allena Pharmaceuticals Inc. The sale prices were between $1.1 and $2.16, with an estimated average price of $1.4.

Sabby Management, Llc sold out a holding in Globus Maritime Ltd. The sale prices were between $10.47 and $25.83, with an estimated average price of $15.67.

Sabby Management, Llc sold out a holding in Celldex Therapeutics Inc. The sale prices were between $9.65 and $15.19, with an estimated average price of $11.71.

Sabby Management, Llc sold out a holding in Soliton Inc. The sale prices were between $6.02 and $8.34, with an estimated average price of $7.18.